For years, the promise of therapeutic cancer vaccines has lingered all but in reality, with the concept of training our immune system to eliminate tumors and prevent recurrences seeming tantalizingly close. However, despite extensive research and experimentation, these vaccines have historically fallen short of expectations, failing to provoke a robust immune response, even in clinical settings.
“There has been a lot of work to make cancer vaccines more effective,” Darell Irvine, a professor in the MIT departments of Biological Engineering and Materials Science and Engineering and a member of the Koch Institute for Integrative Cancer Research at MIT told MIT News.
